00241 Should I Buy

BofAS maintains a Buy rating for ALI HEALTH due to its new development strategies aimed at capturing market opportunities in pharmaceuticals and AI technology. Despite slightly lower-than-expected results for fiscal year 2026 and a forecasted slowdown in short-term profits, the broker is optimistic about long-term revenue growth driven by digitalization and integration with its parent company's platform. They have adjusted the target price downwards but still see potential for monetization through subscriptions and pharmaceutical budgets.